Last reviewed · How we verify

Add-back therapy — Competitive Intelligence Brief

Add-back therapy (Add-back therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy / Adjunctive hormonal therapy. Area: Gynecology / Endometriosis / Uterine Fibroids.

phase 3 Hormone replacement therapy / Adjunctive hormonal therapy Gynecology / Endometriosis / Uterine Fibroids Small molecule Live · refreshed every 30 min

Target snapshot

Add-back therapy (Add-back therapy) — Bio Genuine (Shanghai) Biotech Co., Ltd.. Add-back therapy restores hormonal levels that were suppressed by prior treatment, typically used to mitigate side effects of GnRH agonists in endometriosis or uterine fibroids.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Add-back therapy TARGET Add-back therapy Bio Genuine (Shanghai) Biotech Co., Ltd. phase 3 Hormone replacement therapy / Adjunctive hormonal therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy / Adjunctive hormonal therapy class)

  1. Bio Genuine (Shanghai) Biotech Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Add-back therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/add-back-therapy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: